HROW News & Events

Harrow announced that Iopidine 1% has been assigned a permanent J-Code by the Centers for Medicare & Medicaid Services, CMS. Effective July 1, 2026, Iopidine 1% will be reimbursed when administered in the in-office setting. J-Codes are CMS billing designations that allow physicians to be reimbursed directly for drugs administered in their offices. The assignment of a permanent J-Code removes a longstanding practical barrier to routine use of Iopidine 1% for office-based procedures, making it administratively and economically feasible for physicians to incorporate Iopidine 1% into standard glaucoma and ophthalmic laser procedure workflows.

LogiCare3PL announced it has been selected by Harrow as a distribution partner for Harrow's portfolio of ophthalmic disease management solutions. Effective February 1, 2026, LogiCare3PL is providing both non-title and 3PL title distribution services, supporting distribution of Harrow's products across the U.S. market. The agreement, effective February 1, 2026, covers LogiCare3PL's full suite of 3PL services, including non-title logistics support and title distribution for Harrow's products. Both organizations anticipate continued collaboration as Harrow expands its product offerings.